EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves

Déanne Malenfant, Kelly Summers, Shannon Seney, Donna McBain, Lisa Petrlich, Sharon Watson, Louise Vanderhoek, Nooshin Samadi, Ashley Bonner, Janet Pope

ISRN Rheumatology · 2011

DOI: 10.5402/2011/580704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Rheumatology, 2011. Verfasst von Déanne Malenfant und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Western Ontario, London, ON, Canada N6A 5C1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives .To perform a 6-week double-blind RCT in Raynaud's phenomenon (RP) comparing the plant extract St. John's Wort (SJW) to placebo.

Methods

RP patients having at least 7 attacks per week were stratified by primary and secondary RP and within secondary by systemic sclerosis or other connective tissue disease. Subjects completed a daily standardized diary recording all RP attacks (frequency, duration and severity). Serum levels of 18 inflammatory and angiogenic cytokines were measured pre- and post-treatment.

Results

Eighteen patients completed the study; 8 received SJW and 10 placebo. The decrease in mean number of attacks per day was 0.75 with SJW and 1.01 with placebo, P = 0.06 . Attack duration and severity were not different between groups. Cytokine analyses demonstrated no between-groups differences. Combining treatment groups, those with >50% improvement in frequency of attacks yielded a significant increase in E-selectin ( P = 0.049 ), MMP-9 ( P = 0.011 ), G-CSF ( P = 0.02 ), and VEGF ( P = 0.012 ) pre- versus post-treatment. A ≥50% improvement in severity of attacks corresponded to a significant increase in levels of sVCAM-1 ( P = 0.003 ), sICAM-1 ( P = 0.007 ), and MCP-1 ( P = 0.004 ).

Conclusions

There were no clinical or biomarker benefit of SJW versus placebo in RP. However, combining all patients, there were changes in some cytokines that may be further investigated.

Autor:innen und Institutionen

  • Department of Medicine, University of Western Ontario, London, ON, Canada N6A 5C1.

Zitieren

APA

Malenfant, D., Summers, K., Seney, S., McBain, D., Petrlich, L., Watson, S., Vanderhoek, L., Samadi, N., Bonner, A., & Pope, J. (2011). Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves. ISRN Rheumatology. https://doi.org/10.5402/2011/580704

Vancouver

Malenfant D, Summers K, Seney S, McBain D, Petrlich L, Watson S, et al. Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves. ISRN Rheumatology. 2011. doi:10.5402/2011/580704

BibTeX
@article{Malenfant2011,
  author = {Malenfant, Déanne and Summers, Kelly and Seney, Shannon and McBain, Donna and Petrlich, Lisa and Watson, Sharon and Vanderhoek, Louise and Samadi, Nooshin and Bonner, Ashley and Pope, Janet},
  title = {Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves},
  journal = {ISRN Rheumatology},
  year = {2011},
  doi = {10.5402/2011/580704}
}
Kostenlos starten →